Week 52 results for HAQ-DI and SF-36 scores.
| Placebo + MTX → Golimumab + MTX, n = 123* | Combined Golimumab + MTX, n = 178 | |
|---|---|---|
| HAQ-DI | ||
| Improvement from baseline | 0.39 ± 0.58 | 0.54 ± 0.61 |
| p = 0.031 | ||
| Patients with improvement ≥ 0.25, n (%) | 77 (62.6) | 132 (74.2) |
| p = 0.032 | ||
| SF-36 PCS | ||
| Improvement from baseline | 6.97 ± 10.42 | 8.43 ± 9.16 |
| p = 0.175 | ||
| Patients with improvement ≥ 5, n (%) | 63 (51.2) | 110 (61.8) |
| p = 0.068 | ||
| SF-36 MCS | ||
| Improvement from baseline | 4.45 ± 9.73 | 4.83 ± 10.56 |
| p = 0.874 | ||
| Patients with improvement ≥ 5, n (%) | 51 (41.5) | 77 (43.3) |
| p = 0.757 |
↵* Patients who discontinued the study before early escape or crossover to golimumab were not included in this analysis. Data are mean ± SD improvement from baseline unless otherwise noted. HAQ-DI: Disability Index of the Health Assessment Questionnaire; MCS: mental component summary; MTX: methotrexate; PCS: physical component summary; SF-36: Medical Outcomes Study Short Form-36.